Zacks Investment Research downgraded shares of PEREGRINE PHARM (PPHM) from OUTPERFORM to NEUTRAL on November 27, 2012, with a target price of $0.90.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus infection. The company is pursuing three separate clinical trials in cancer and HCV infection with its lead product candidate bavituximab and Cotara. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and bio-manufacturing services for both Peregrine and outside customers.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on PEREGRINE PHARM (PPHM),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment